{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:23:48Z","timestamp":1790742228469,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1038\/s41443-020-0271-3","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T10:03:12Z","timestamp":1586944992000},"page":"376-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Collagenase clostridium histolyticum is no longer available in Europe: what does this mean for our patients with Peyronie\u2019s Disease?"],"prefix":"10.1038","volume":"33","author":[{"given":"Matthew J.","family":"Ziegelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal A.","family":"Yafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"271_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2019.01.001","volume":"125","author":"DCJ Mohede","year":"2019","unstructured":"Mohede DCJ, de Jong IJ, van Driel MF. Medical treatments of Peyronie\u2019s disease: past, present, and future. Urology. 2019;125:1\u20135.","journal-title":"Urology"},{"key":"271_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41585-018-0117-7","volume":"16","author":"P Tsambarlis","year":"2019","unstructured":"Tsambarlis P, Levine LA. Nonsurgical management of Peyronie\u2019s disease. Nat Rev Urol. 2019;16:172\u201386.","journal-title":"Nat Rev Urol"},{"key":"271_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.juro.2015.05.098","volume":"194","author":"A Nehra","year":"2015","unstructured":"Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie\u2019s disease: AUA guideline. J Urol. 2015;194:745\u201353.","journal-title":"J Urol"},{"key":"271_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/andr.292","volume":"3","author":"J Sullivan","year":"2015","unstructured":"Sullivan J, Moskovic D, Nelson C, Levine L, Mulhall J. Peyronie\u2019s disease: urologist\u2019s knowledge base and practice patterns. Andrology. 2015;3:260\u20134.","journal-title":"Andrology"},{"key":"271_CR5","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.5489\/cuaj.5255","volume":"12","author":"AJ Bella","year":"2018","unstructured":"Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie\u2019s disease and congenital penile curvature. Can Urol Assoc J. 2018;12:E197\u2013e209.","journal-title":"Can Urol Assoc J"},{"key":"271_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.sxmr.2018.11.002","volume":"7","author":"MG Cowper","year":"2019","unstructured":"Cowper MG, Burkett CB, Le TV, Scherzer N, Hellstrom WJG. Penile stretching as a treatment for Peyronie\u2019s Disease: a review. Sex Med Rev. 2019;7:508\u201315.","journal-title":"Sex Med Rev"},{"key":"271_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/sj.ijir.3900917","volume":"14","author":"LA Levine","year":"2002","unstructured":"Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie\u2019s disease: a review. Int J Impot Res. 2002;14:324\u20138.","journal-title":"Int J Impot Res"},{"key":"271_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease. J Urol. 2006;176:394\u20138.","journal-title":"J Urol"},{"key":"271_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"271_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40261-019-00867-5","volume":"40","author":"SM Hoy","year":"2020","unstructured":"Hoy SM. Collagenase clostridium histolyticum: a review in Peyronie\u2019s disease. Clin Drug Investig. 2020;40:83\u201392.","journal-title":"Clin Drug Investig"},{"key":"271_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/bmb\/ldw020","volume":"118","author":"F Smeraglia","year":"2016","unstructured":"Smeraglia F, Del Buono A, Maffulli N. Collagenase clostridium histolyticum in Dupuytren\u2019s contracture: a systematic review. Br Med Bull. 2016;118:149\u201358.","journal-title":"Br Med Bull"},{"key":"271_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jsxm.2019.09.022","volume":"17","author":"S Sukumar","year":"2020","unstructured":"Sukumar S, Pijush DB, Brandes S. Impact of the advent of collagenase clostridium histolyticum on the surgical management of Peyronie\u2019s disease: a population-based analysis. J Sex Med. 2020;17:111\u20136.","journal-title":"J Sex Med"},{"key":"271_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.urology.2018.06.049","volume":"120","author":"FA Yafi","year":"2018","unstructured":"Yafi FA, Diao L, DeLay KJ, DeYoung L, Talib R, Alzweri L, et al. Multi-institutional prospective analysis of intralesional injection of collagenase clostridium histolyticum, tunical plication, and partial plaque excision and grafting for the management of Peyronie\u2019s disease. Urology. 2018;120:138\u201342.","journal-title":"Urology"},{"key":"271_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.sxmr.2019.08.002","volume":"8","author":"ARG Barbosa","year":"2020","unstructured":"Barbosa ARG, Takemura LS, Cha JD, Carneiro A, Lemos GC, Glina S, et al. Surgical treatment of Peyronie\u2019s disease: systematic review of techniques involving or not tunica albuginea incision. Sex Med Rev. 2020;8:324\u201332.","journal-title":"Sex Med Rev"},{"key":"271_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.urology.2016.04.049","volume":"94","author":"KK Yang","year":"2016","unstructured":"Yang KK, Bennett N. Peyronie\u2019s disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143\u20137.","journal-title":"Urology"},{"key":"271_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","volume":"106","author":"MJ Ziegelmann","year":"2017","unstructured":"Ziegelmann MJ, Viers BR, Montgomery BD, Westerman ME, Savage JB, Trost LW. Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for Peyronie disease. Urology. 2017;106:107\u201312.","journal-title":"Urology"},{"key":"271_CR17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","volume":"195","author":"MJ Ziegelmann","year":"2016","unstructured":"Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie\u2019s disease. J Urol. 2016;195:1051\u20136.","journal-title":"J Urol"},{"key":"271_CR18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/jsm.12910","volume":"12","author":"D Papagiannopoulos","year":"2015","unstructured":"Papagiannopoulos D, Yura E, Levine L. Examining postoperative outcomes after employing a surgical algorithm for management of Peyronie\u2019s disease: a single-institution retrospective review. J Sex Med. 2015;12:1474\u201380.","journal-title":"J Sex Med"},{"key":"271_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","volume":"194","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie\u2019s disease. J Urol. 2015;194:754\u20138.","journal-title":"J Urol"},{"key":"271_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","volume":"9","author":"MR Abern","year":"2012","unstructured":"Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie\u2019s disease. J Sex Med. 2012;9:288\u201395.","journal-title":"J Sex Med"},{"key":"271_CR21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","volume":"16","author":"M Alom","year":"2019","unstructured":"Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie\u2019s disease. J Sex Med. 2019;16:891\u2013900.","journal-title":"J Sex Med"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41443-020-0271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41443-020-0271-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41443-020-0271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:31:41Z","timestamp":1684618301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-020-0271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1038\/s41443-020-0271-3","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FAY: Coloplast Corporation (consultant, advisory board) and Endo Pharmaceuticals (consultant, advisory board, speaker). MJZ: no pertinent conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}